NXT2B

Navinci Diagnostics AB is a biotechnology company based in Uppsala, Sweden, specializing in biomolecular analysis for cancer and prenatal diagnostics. The company develops proprietary technology for detecting and quantifying proteins, their interactions, and modifications in various biological samples, including tissue, cells, and blood. Navinci offers a range of products, including universal kits for detecting proteins in cultured cells and fresh-frozen or formalin-fixed paraffin-embedded samples, as well as target-specific kits that are pre-optimized for specific variables. Additionally, Navinci provides in-house immunostaining and custom assay services that combine antibody-based proteomic technologies with fluorescence readouts, facilitating advanced research in human biology and drug development.

Vivolux AB is a pharmaceutical company based in Mölndal, Sweden, focusing on drug discovery and development for cancer treatment. Founded in 2006, the company specializes in creating innovative therapies, including VLX600, an iron chelator that disrupts mitochondrial respiration to induce tumor cell death, and VLX1570, which inhibits the proteasome to promote apoptosis in cancer cells. Vivolux employs advanced culture systems for drug screening and lead optimization, enhancing the research capabilities of medical scientists. Their expertise lies in mechanistic studies of anticancer drugs, integrating a deep understanding of molecular interactions at the cellular level to develop effective treatments.